A Phase 1, First-in-Human, Open-label, Dose Escalation Study of MGD013, a Bispecific DART® Protein Binding PD-1 and LAG-3 in P
Targeted Anti‐Tumor Immunotherapy Using Tumor Infiltrating Cells - Xie - 2021 - Advanced Science - Wiley Online Library
MOAs of 18 bsAbs in Chinese clinical trials. (A) Among the 18 bsAbs,... | Download Scientific Diagram
A review of bispecific antibodies and antibody constructs in oncology and clinical challenges - ScienceDirect
IJMS | Free Full-Text | Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer | HTML
IJMS | Free Full-Text | LAG-3 as a Potent Target for Novel Anticancer Therapies of a Wide Range of Tumors | HTML
PDF) 313 A phase 1 evaluation of tebotelimab, a bispecific PD-1 x LAG-3 DART® molecule, in combination with margetuximab in patients with advanced HER2+ neoplasms
IJMS | Free Full-Text | Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer | HTML
Clinical landscape of LAG-3-targeted therapy - Immuno-Oncology and Technology
By Besting Herceptin, The Future Is Bright For MacroGenics (NASDAQ:MGNX) | Seeking Alpha
2020 ASCO Immuno-Oncology Abstracts | Journal of Clinical Oncology
A Phase 1, Open-Label Study of MGD013 (Tebotelimab), a Bispecific DART® Molecule Binding PD-1 and LAG-3, in Patients with Relap
![Top 10 Cholangiocarcinoma Clinical Trials [2022 Studies] | Power](https://pwr-og-img.withpower.com/Apply%20to%20this%20Phase%202%20clinical%20trial%20treating%20FGFR3%20Alteration,%20FGFR2%20Fusion,%20Cholangiocarcinoma,%20FGFR1%20Alteration,%20FGFR2%20Gene%20Mutation:%0A%0ATT-00420%20for%20Cholangiocarcinoma.png?md=1 "Top 10 Cholangiocarcinoma Clinical Trials [2022 Studies] | Power")
Top 10 Cholangiocarcinoma Clinical Trials [2022 Studies] | Power
FORM 8-K
Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor. - Abstract - Europe PMC
Emerging new therapeutic antibody derivatives for cancer treatment | Signal Transduction and Targeted Therapy
Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor
![Top 10 Cholangiocarcinoma Clinical Trials [2022 Studies] | Power](https://pwr-og-img.withpower.com/Apply%20to%20this%20Phase%202%20clinical%20trial%20treating%20Cholangiocarcinoma,%20Neoplasms,%20Malignant%20Solid%20Neoplasms,%20Refractory%20Malignant%20Solid%20Neoplasm,%20Refractory%20Cholangiocarcinoma:%0A%0ACeralasertib%20for%20Cholangiocarcinoma.png?md=1 "Top 10 Cholangiocarcinoma Clinical Trials [2022 Studies] | Power")
Top 10 Cholangiocarcinoma Clinical Trials [2022 Studies] | Power
Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups | Nature Immunology
A review of bispecific antibodies and antibody constructs in oncology and clinical challenges - ScienceDirect
FORM 8-K
The state of the art of bispecific antibodies for treating human malignancies | EMBO Molecular Medicine
![Top 10 Cholangiocarcinoma Clinical Trials [2022 Studies] | Power](https://pwr-og-img.withpower.com/Apply%20to%20this%20Phase%202%20clinical%20trial%20treating%20Cholangiocarcinoma,%20Intrahepatic%20Cholangiocarcinoma:%0A%0ADexamethasone%20for%20Cholangiocarcinoma.png?md=1 "Top 10 Cholangiocarcinoma Clinical Trials [2022 Studies] | Power")
Top 10 Cholangiocarcinoma Clinical Trials [2022 Studies] | Power
Frontiers | Clinical Insights Into Novel Immune Checkpoint Inhibitors
asco2020_mgd013phase1
MACROGENICS, INC.
